Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
In the SURMOUNT-1 trial, tirzepatide at the highest dose (15 mg) produced average weight loss of 22.5% versus approximately 15% for semaglutide in comparable trials
If you have questions, ask uswere happy to help
Clinical Endocrinology
This decision was based on data suggesting that manufacturers could now meet the current and projected demand for injectable semaglutide, the active ingredient in popular medications like Ozempic and Wegovy
This not only gives the developers a chance to create personalized experiences and improve medication adherence, but also allows them to gather critical data on patient preferences, behaviors, and care outcomes
US$ 25.31
US$ 20.45
US$ 21.32
US$ 22.14
